drugset / Trial / NCT03201848

The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia

NCT03201848

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (Qi Yin deficiency).

Timeline

Start
2017-11-16
Primary completion
2023-10-14
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Huaiqihuang Granule Unknown